1. Home
  2. CUK vs ALNY Comparison

CUK vs ALNY Comparison

Compare CUK & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carnival Plc ADS ADS

CUK

Carnival Plc ADS ADS

HOLD

Current Price

$27.42

Market Cap

38.7B

ML Signal

HOLD

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

HOLD

Current Price

$300.21

Market Cap

39.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CUK
ALNY
Founded
1972
2002
Country
United States
United States
Employees
117000
115
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.7B
39.0B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
CUK
ALNY
Price
$27.42
$300.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
22
28
Target Price
$33.99
$471.00
AVG Volume (30 Days)
5.2M
892.2K
Earning Date
03-27-2026
04-30-2026
Dividend Yield
0.59%
N/A
EPS Growth
N/A
206.88
EPS
N/A
2.33
Revenue
N/A
$1,037,418,000.00
Revenue This Year
$7.64
$52.67
Revenue Next Year
$3.42
$31.48
P/E Ratio
$16.36
$131.23
Revenue Growth
N/A
22.88
52 Week Low
$20.05
$284.28
52 Week High
$33.72
$495.55

Technical Indicators

Market Signals
Indicator
CUK
ALNY
Relative Strength Index (RSI) 53.55 49.67
Support Level $25.81 $299.75
Resistance Level $27.85 $331.27
Average True Range (ATR) 0.95 9.17
MACD -0.07 1.91
Stochastic Oscillator 46.41 74.19

Price Performance

Historical Comparison
CUK
ALNY

About CUK Carnival Plc ADS ADS

Carnival is the largest global cruise company, with nearly 100 ships in service. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe. It recently folded its P&O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted nearly 14 million guests in 2025.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Share on Social Networks: